Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.
about
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Exposure-Response of Veliparib ...... th Hematological Malignancies.
@en
type
label
Exposure-Response of Veliparib ...... th Hematological Malignancies.
@en
prefLabel
Exposure-Response of Veliparib ...... th Hematological Malignancies.
@en
P2093
P2860
P1476
Exposure-Response of Veliparib ...... th Hematological Malignancies.
@en
P2093
Jacqueline M Greer
Jiuping Jay Ji
Jogarao Gobburu
Judith Karp
Keith W Pratz
Mathangi Gopalakrishnan
Michelle A Rudek
Richard L Piekarz
Shailly Mehrotra
P2860
P356
10.1158/1078-0432.CCR-17-0143
P407
P577
2017-07-27T00:00:00Z